Ritedose Launches Critical Single-Dose Syringe Product Amid National Drug Shortage: <em>Lidocaine Hydrochloride 1% 100 mg/10 mL</em>
COLUMBIA, S.C. (October 17, 2022) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Lidocaine Hydrochloride 1% 100 mg/10 mL. It is a ready-to-use drug shortage solution for hospital pharmacies across the country. Ritedose is a division of The Ritedose Corporation,
Ritedose Reaches Milestone with Asset Purchase <br><em>Becomes largest generic drug maker of its kind</em>
COLUMBIA, S.C.—The Ritedose Corporation, LLC now offers the most complete nebulized inhalation drug portfolio in the industry with the purchase of the Arformoterol Tartrate asset from PAI Pharma of Greenville, S.C.